Esophageal atresia is a common and life-threatening birth defect with a poorly understood etiology. In this study, we analyzed the sequence variants of coding regions for a set of esophageal atresia-related genes including MYCN, SOX2, CHD7, GLI3, FGFR2 and PTEN for mutations using PCR-based target enrichment and nextgeneration sequencing in 27 patients with esophageal atresia. Genomic copy number variation analysis was performed using Affymetrix SNP 6.0. We found a de novo heterozygous mutation in the N-terminal region of the GLI3 gene (c.332 T N C, p.M111T) in a patient with esophageal atresia and hemivertebrae. The N-terminal region (amino acids 1-397) of GLI3 contains the repressor domain, which interacts with SKI family proteins. Using the co-immunoprecipitation assay, we found that interaction of GLI3 with the SKI family protein SKIL was significantly compromised by the p.M111T mutation of GLI3. Thus far, all the identified mutations mapped within the repressor domain of GLI3 were nonsense and frame-shift mutations. In this study, a missense mutation was initially detected in this region. Our finding is the first to link this GLI3 gene mutation with esophageal atresia in humans, which was previously suggested in an animal model.
Introduction
Esophageal atresia (EA) is a developmental defect of the upper gastrointestinal tract in which the continuity between the upper and lower esophagus is lost. Esophageal atresia with or without tracheo-esophageal fistula (TEF) is a rare malformation, occurring in approximately 1 in 3500 births [1] . Although the underlying molecular mechanism remains obscure in most patients with EA/TEF, it has been associated with a wide spectrum of genetic syndromes caused by genetic alterations including mutations in single genes or chromosome aberrations [2] .
Approximately 6% to 10% of syndromic EA/TEF is associated with chromosomal anomalies [3] . The majority is represented by trisomies (trisomy 13, 18, 21) [2, 4] or microdeletions of 22q11 [5] , 17q22-17q23.3 [6] and 16q24.1 [7] . Meanwhile, mutations of MYCN, SOX2 and CDH7 have also been reported to be responsible for syndromic EA, such as Feingold syndrome, AEG syndrome (Anophthalmia-esophagealgenital syndrome) and CHARGE association (coloboma, heart anomaly, choanal atresia, retardation, and genital and ear anomalies) [8] . Deletions and mutations in the GLI3 and FGFR2 genes are responsible for PallisterHall syndrome and Apert syndrome, respectively, in which EA is infrequently reported [9] [10] [11] . In rare cases, mutations in PTEN have been reported in the VATER association (vertebral defects, anal atresia, tracheoesophageal fistula with esophageal atresia, and radial or renal dysplasia) [12] .
In this study, we searched for sequence variants in the proteincoding regions of the human MYCN, SOX2, CHD7, GLI3, FGFR2 and PTEN genes by PCR-based target enrichment followed by next-generation sequencing using the Ion Torrent Personal Genome Machine™ (PGM TM , Life Technologies, Carlsbad, CA). We also analyzed genomic copy number variants (CNVs) in 27 patients with EA/TEF. We found a de novo heterozygous mutation in the N-terminal region of the GLI3 gene (c.332 T N C, p.M111T). Our finding is the first to link the GLI3 gene mutation with esophageal atresia in humans, which was previously suggested in an animal model.
Materials and methods

Subjects and DNA extraction
The subjects included 27 neonates with either isolated (6 neonates, 22.2%) or syndromic (21 neonates, 77.8%) forms of EA/TEF (Table 1) . Among these neonates, 14 (52%) were female and 13 (48%) were male. Routine chromosome analysis was normal. The samples used in this study were collected with appropriate informed consent and the approval of the ethics committees of Children's Hospital, Fudan University.
Genomic DNA was extracted from whole blood using the QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany). DNA concentration was measured using a Nano-Drop spectrophotometer (ND-1000, Thermo Fisher Scientific, Waltham, MA).
Candidate genes sequencing
Analysis of the protein-coding regions of the human MYCN, SOX2, CHD7, GLI3, FGFR2 and PTEN genes were performed using Ion Torrent PGM 
Validation by Sanger sequencing
The variants were validated by PCR followed by direct Sanger sequencing using an automated sequencer (3500XL Genetic Analyzer, Applied Biosystems, Foster City, CA).
In vitro binding assay and co-immunoprecipitation
The human N-terminal GLI3 (397 amino acids) gene was obtained from GenScript (Piscataway, NJ). The hGli3N sequence was inserted into pRK5 with an HA tag to produce the WT hGli3N plasmid. The hGli3N mutation was generated based on this construct. In brief, Gli3N-M111T was generated using KOD-Plus (Toyobo, Osaka, Japan) according to the manufacturer's instructions. Primers used in the point mutation assay were For 5′-acggaccccaggaatggttacatgg-3′ and Rev 5′-ggcaaacaccgtcccgcggtacggc-3′. Antibodies used in this study were against the HA epitope tag (#M20013, Abmart) and SKIL (#19218-1-AP, Proteintech). The plasmid expressing either HA-tagged wild-type or p.M111T-mutant N-terminal GLI3 (397 amino acids) was transfected into 293 T cells.
For co-IP of 293 T cells, HEK293T cells were plated on 6-well plates, and transfection was performed when the cells reached 50% confluence. Lipofectamine2000 (Invitrogen, Carlsbad, CA) was used for transfection. Table 1 Summary of clinical features of all included patients. Note: PDA: patent ductus arteriosus, PFO: patent foramen ovale, VSD: ventricular septal defect, PPHN: persistent pulmonary hypertension, ASD: atrial septal defect, PLSVC: persistent left superior vena cava, TAPVD: total anomalous pulmonary venous drainage, DORV: double outlet of right ventricle.
Patient ID
Gender Isolated/non-isolated Gastrointestinal Skeletal Heart Urogenital Dysmorphic Additional anomalies
Then, 2 μg of HA-tagged hGli3N was added per well in 6-well plates. Cells were harvested 48 h after transfection. The cells were harvested and lysed for 10 min at 4°C in RIPA buffer. A total of 25% of the supernatant was saved for the input control, and the rest was incubated with 2 μg anti-HA agarose beads (Abmart, Beijing, China) overnight at 4°C. The immune complex was washed three times with the lysis buffer, then boiled in 1× SDS loading buffer with 20 mM DTT and resolved by 8% SDS-PAGE. The gel was transferred onto a PVDF membrane (Amersham Pharmacia Biotech, Uppsala, Sweden), and the membrane was blocked with 5% milk in TBST buffer for 1 h. The membrane was then incubated overnight at 4°C with 1:1000 anti-SKIL antibodies, washed three times in TBST, then incubated for 2 h at room temperature with 1:3000 secondary antibodies, and after three times washing in TBST, the signals were revealed by HRP reaction using the Supersignal chemiluminescent substrate (Pierce, Rockford, IL). The co-immunoprecipitated endogenous SKIL was normalized to the HA-tagged hGli3N. The data were analyzed with Students' T-test with the GraphPad Prism software.
Whole-genome high-resolution SNP array analysis
Affymetrix Genome-Wide Human SNP Array 6.0 was used to perform copy number variation analysis. The copy number variation data of 2 patients (614, 617) were obtained from previous results with the 244 K array comparative genomic hybridization (CGH) platform (Agilent, Santa Clara, CA). We used Affymetrix Genotyping Console (GTC) V.4.0 and ChAS V.2.0 software to call CNVs, with all the parameter thresholds set to default values. All annotated CNV genomic regions were based on the hg19 (NCBI) human genome assembly. Common variants were evaluated using the Database of Genomic Variants (DGV) and were excluded from further analysis. Quantitative realtime PCR was used for validation of CNVs. The ALB and TBP genes were used as controls as previously described [13, 14] . Copy number gain or loss was determined by the comparative C T method. The relative copy number values for each CNV between 0.8 and 1.2 were considered to be normal while values ≥1.3 and ≤0.7 were considered as evidences of duplication and deletion, respectively.
Results
Candidate gene sequencing analysis
We pooled 10 cases of barcoded sample libraries on one 316™ chip for sequencing using the Ion PGM TM . We obtained a total alignment of bases from 416 Mb to 478 Mb, with an average mean depth of coverage of 375-421 Mb. We identified 156 variants from 27 probands (Supplementary Table 1 ) and an average of 5.78 variants per proband. These included 126 known single-nucleotide polymorphisms (SNPs), 11 VUSs, and 19 variants were called on homopolymer sites. Variant calls from 5 noncoding homopolymer sites were filtered out to avoid homopolymer-associated base-calling errors. Of the 11 VUSs, 9 were in coding regions (2 were synonymous variants), and 2 were in intronic regions. Sanger sequencing confirmed 5 of the 7 missense variants in the coding regions (Table 2 ). Of the 5 confirmed variants, the variant of GLI3 (NM_000168.5, c.332 T N C, p.M111T) was predicted to be damaging in silico by both SIFT and PolyPhen2, and the variant in CHD7 (NM_017780.3, c.2360C N T, p.787S N F) was predicted to be damaging in silico by PolyPhen2 but tolerated by SIFT. The p.M111T variant of GLI3 is novel and de novo (Fig. 1A and D) . Unfortunately, the parents were not available to test the CHD7 p.787S N F variant.
The phenotypes of the patients with the GLI3 (p.M111T) and CHD7 (p.S787F) variants were esophageal atresia with hemivertebrae and isolated esophageal atresia, respectively.
In vitro binding assay and co-immunoprecipitation
GLI3 is a Ski-interacting protein. The N-terminal region of GLI3 (amino acids 1-397) contains the repressor domain responsible for interacting with Ski [15, 16] . To investigate whether the p.M111T mutation of GLI3 affects the interaction of GLI3 with SKI family proteins, we examined the interaction between wild-type and p.M111T-mutant GLI3 with endogenous SKIL, a critical SKI family protein, using coimmunoprecipitation assay.
As shown in Fig. 1E , we found that the interaction between GLI3 with SKIL was significantly compromised in the GLI3 p.M111T mutant (Fig. 1E ). These data suggested that the p.M111T mutation affects the physiological function of GLI3 by disrupting its interaction with SKI family proteins.
Copy number variation analysis
We identified a total of 969 CNVs in 27 probands. Among these CNVs, 266 were mapped in the intronic regions and 693 CNVs were reported in DGV that were excluded for further analysis. Only nine CNVs from 8 probands were rare and mapped in the gene rich regions. Four of them, ranging in size from 175.2 Kb to 382.2 Kb at 3p14.1, 4q21.22, 10q24.2 and 17q24.3, were validated by qPCR (Table 3, Fig. 2 ). The CNV in proband 386 was de novo, but the parents of the other three patients were not available for testing. Clinical significance was evaluated based on the literature review and genome annotation of gene content and functions. There was no evidence immediately supporting the clinical significance of these CNVs. Case W43 is a male patient with esophageal atresia IIIb and ventricular septal defect. A duplication was found at 3p14.1 with an estimated size of 382 kb, encompassing the SLC25A26 and LRIG1 genes. The 3p14 region is frequently detected in various types of human cancers [17] . The LRIG1 gene has been proposed to interact with and counteract the effects of growth factor receptors such as EGFR [18] , thereby functioning as a tumor suppressor [19] . Case 329 is a male patient with esophageal atresia IIIb and hemivertebrae. A duplication was found at 4q21.23 with an estimated size of 365 kb, encompassing the HNRNPD, HNRPDL, ENOPH1 and TMEM150C genes. Deletion of this region induces 4q21 deletion syndrome, which is characterized by growth restriction and mental retardation [20] . Case 386 is a female patient with isolated esophageal atresia III. De novo microduplication was found at 10q24.2 with an 
estimated size of 175 kb, encompassing the PYROXD2, MIR1287, HPS1 and HPSE2 genes. The 10q24 duplication has previously been implicated in split hand foot malformation, but no patient with EA/TEF has been reported [21] . Case 614 is a male patient with esophageal atresia, ventricular septal defect, coagulation dysfunction, hypothyroidism and hypokalemia. A duplication was found at 17q24.3 with an estimated size of 249 kb, encompassing the SLC39A11 gene. Neither deletion/ duplication of this region nor abnormality of the SLC39A11 gene has been related to EA/TEF. Although chromosome anomalies have been reported in approximately 6%-10% of individuals with EA/TEF, none of the detected CNVs are proposed to contribute towards gastrointestinal malformations. Copy number variants may not be the common cause in the investigated EA/TEF cohorts.
Discussion
The GLI3 gene encodes a zinc finger protein belonging to the GLI family and functions as a transcription factor that regulates the Sonic hedgehog (SHH) signal transduction pathway [22] . The SHH-GLI pathway is one of many signaling pathways controlling the development of the primitive gut. The importance of SHH signaling in esophageal development was confirmed with Gli mutant mice, in which a 50% reduction of Gli3 expression in Gli2 -/ -mice resulted in EA/TEF and severe lung deficiencies [23] . These results suggest that mutations in the GLI3 gene may be involved in human foregut malformations. However, to our knowledge, no GLI3 gene structure aberrations or sequence variations were detected in patients with isolated or syndromic EA/TEF.
Mutations in GLI3 are associated with two dominant human syndromes: Greig cephalopolysyndactyly syndrome (GCPS) and PallisterHall syndrome (PHS) [9] . The genotype-phenotype correlation of the GLI3 gene has been demonstrated based on mutation location and classification. Mutations upstream of the zinc finger domain (the repressor domain) or within the zinc finger domain of the GLI3 gene are associated with GCPS; mutations downstream of the zinc finger region including the protease cleavage site correlate with PHS ( Fig. 1B and C) . A similar phenomenon was observed in the mouse homologue [24] . The protein truncation mutations in GLI3 are associated with PHS, whereas haploinsufficiency of GLI3 induces GCPS [25, 26] . These results strongly suggest that these two allelic disorders have distinct modes of pathogenesis. In this study, we present a female patient (No. 613) with esophageal atresia IIIa and hemivertebrae, carrying a c.332 T N C transition caused by a heterozygous mutation, p.M111T, in exon 3 of the GLI3 gene. This mutation is de novo and is located in the N-terminal region. The N-terminal region of GLI3 contains the repressor domain [27] . Thus far, all identified mutations mapped within the repressor domain were nonsense mutations (T122X, L162X, and E236X) or frame-shift mutations (M309fs, L346fs and E411fs), which should remove most regions of the 1580 amino acid wild-type protein and induce GCPS by haploinsufficiency [24, 26, 28, 29] . However, we present a missense mutation, p.M111T, in this region. Using co-immunoprecipitation assays, we found that the interaction of GLI3 with the SKI family protein SKIL is significantly compromised by the p.M111T mutation of GLI3. This is a milder functional defect than haploinsufficiency; therefore, it may contribute to a less severe and atypical phenotype of Pallister-Hall syndrome. PHS is a disorder that affects the development of many parts of the body that is characterized by hypothalamic hamartoma, central and postaxial polydactyly, imperforate anus, renal anomalies, and foregutrelated anomalies. Although bifid epiglottis is a common finding in PHS, posterior laryngeal and tracheoesophageal cleft are uncommon in this disorder [30] . Likewise, hemivertebrae is not a major criterion for diagnosis of PHS and is present only in a few cases [31, 32] . We conclude that the missense mutation in the repressor domain of the GLI3 gene is associated with esophageal atresia and hemivertebrae, which are partially consistent with PHS.
Zentner et al. [33] reviewed 254 individuals and found that approximately 19% of CHD7 mutation-positive CHARGE syndrome patients also present with EA/TEF. Case 328, a female patient with esophageal atresia III and patent foramen ovale, carried the transition c.2360C N T, which causes the heterozygous variant p.787S N F in exon 4 of CHD7 (NM_017780.3). The p.787S N F residue is proximal to the chromatin organization modifier (chromo) domain, which is a conserved region. Unfortunately, the parents were not available to test for the CHD7 p.787S N F variant in this study. Although it remains to be confirmed, we predicted that this variant may contribute to EA/TEF.
In this study, we analyzed genomic copy number variants and screened six esophageal atresia-related genes for protein-coding variants. However, several limitations in our study may still be worth discussing and may be improved in the future. For example, several other genes, such as EFTUD2 and HOXD13, which are known to cause EA, will be included in further studies. Secondly, the role of GLI3 in the pathogenesis of EA/TEF should be further investigated by extending the same analysis to a larger sample size and by conducting the study in vivo.
In summary, we detected a de novo heterozygous mutation in the GLI3 gene in a patient with esophageal atresia and hemivertebrae. This mutation affected the protein-protein interaction between GLI3 and SKIL, which suggests the functional relevance of the mutation. To our knowledge, this is the first report that links a GLI3 gene mutation to esophageal atresia in humans, which has been suggested in studies with animal models. Our findings suggest that esophageal atresia should be added to the clinical spectrum of phenotypes caused by mutations in GLI3.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.bbadis.2014.05.001.
